Types and epidemiology of cancer-related neuropathic pain: the intersection of cancer pain and neuropathic pain.

Mark J. Lema, Kathleen M. Foley, Frederick H. Hausheer

Research output: Contribution to journalArticle

Abstract

Neuropathic pain--pain resulting from a lesion, damage, or dysfunction of the somatosensory nervous system--can arise through several distinct etiologies ranging from toxicity, surgery, radiation, and trauma to congenital disorders. Neuropathic pain is widely recognized as a common consequence of cancer and results from administration of several common oncology drugs. It not only impacts quality of life, but it also impacts patient outcomes because of resulting treatment delays, dose reductions, and discontinuations. We estimate that the cost of the problem in the U.S. alone is approximately $2.3 billion. Despite its widely recognized importance, there is a paucity of reliable information available regarding the incidence, prevalence of patient-and physician-reported severity, and time course of cancer-related neuropathic pain. To address this severe knowledge gap, we need new, high-quality, population-based studies of individual cancer pain syndromes and conditions. However, in order to gather this information, we also need substantial improvements in the specific classification of cancer-related neuropathic syndromes and better validated diagnostic tools that can help to elucidate the incidence, prevalence, severity, and potential economic impact of cancer-associated neuropathies.

Original languageEnglish (US)
Pages (from-to)3-8
Number of pages6
JournalOncologist
Volume15 Suppl 2
StatePublished - 2010
Externally publishedYes

Fingerprint

Neuralgia
Epidemiology
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Neoplasms
Incidence
Nervous System
Economics
Quality of Life
Radiation
Physicians
Costs and Cost Analysis
Pain
Wounds and Injuries
Pharmaceutical Preparations
Population
Cancer Pain
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Types and epidemiology of cancer-related neuropathic pain : the intersection of cancer pain and neuropathic pain. / Lema, Mark J.; Foley, Kathleen M.; Hausheer, Frederick H.

In: Oncologist, Vol. 15 Suppl 2, 2010, p. 3-8.

Research output: Contribution to journalArticle

Lema, Mark J. ; Foley, Kathleen M. ; Hausheer, Frederick H. / Types and epidemiology of cancer-related neuropathic pain : the intersection of cancer pain and neuropathic pain. In: Oncologist. 2010 ; Vol. 15 Suppl 2. pp. 3-8.
@article{f7d9af470e0e47768ae56e1faeac16b4,
title = "Types and epidemiology of cancer-related neuropathic pain: the intersection of cancer pain and neuropathic pain.",
abstract = "Neuropathic pain--pain resulting from a lesion, damage, or dysfunction of the somatosensory nervous system--can arise through several distinct etiologies ranging from toxicity, surgery, radiation, and trauma to congenital disorders. Neuropathic pain is widely recognized as a common consequence of cancer and results from administration of several common oncology drugs. It not only impacts quality of life, but it also impacts patient outcomes because of resulting treatment delays, dose reductions, and discontinuations. We estimate that the cost of the problem in the U.S. alone is approximately $2.3 billion. Despite its widely recognized importance, there is a paucity of reliable information available regarding the incidence, prevalence of patient-and physician-reported severity, and time course of cancer-related neuropathic pain. To address this severe knowledge gap, we need new, high-quality, population-based studies of individual cancer pain syndromes and conditions. However, in order to gather this information, we also need substantial improvements in the specific classification of cancer-related neuropathic syndromes and better validated diagnostic tools that can help to elucidate the incidence, prevalence, severity, and potential economic impact of cancer-associated neuropathies.",
author = "Lema, {Mark J.} and Foley, {Kathleen M.} and Hausheer, {Frederick H.}",
year = "2010",
language = "English (US)",
volume = "15 Suppl 2",
pages = "3--8",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",

}

TY - JOUR

T1 - Types and epidemiology of cancer-related neuropathic pain

T2 - the intersection of cancer pain and neuropathic pain.

AU - Lema, Mark J.

AU - Foley, Kathleen M.

AU - Hausheer, Frederick H.

PY - 2010

Y1 - 2010

N2 - Neuropathic pain--pain resulting from a lesion, damage, or dysfunction of the somatosensory nervous system--can arise through several distinct etiologies ranging from toxicity, surgery, radiation, and trauma to congenital disorders. Neuropathic pain is widely recognized as a common consequence of cancer and results from administration of several common oncology drugs. It not only impacts quality of life, but it also impacts patient outcomes because of resulting treatment delays, dose reductions, and discontinuations. We estimate that the cost of the problem in the U.S. alone is approximately $2.3 billion. Despite its widely recognized importance, there is a paucity of reliable information available regarding the incidence, prevalence of patient-and physician-reported severity, and time course of cancer-related neuropathic pain. To address this severe knowledge gap, we need new, high-quality, population-based studies of individual cancer pain syndromes and conditions. However, in order to gather this information, we also need substantial improvements in the specific classification of cancer-related neuropathic syndromes and better validated diagnostic tools that can help to elucidate the incidence, prevalence, severity, and potential economic impact of cancer-associated neuropathies.

AB - Neuropathic pain--pain resulting from a lesion, damage, or dysfunction of the somatosensory nervous system--can arise through several distinct etiologies ranging from toxicity, surgery, radiation, and trauma to congenital disorders. Neuropathic pain is widely recognized as a common consequence of cancer and results from administration of several common oncology drugs. It not only impacts quality of life, but it also impacts patient outcomes because of resulting treatment delays, dose reductions, and discontinuations. We estimate that the cost of the problem in the U.S. alone is approximately $2.3 billion. Despite its widely recognized importance, there is a paucity of reliable information available regarding the incidence, prevalence of patient-and physician-reported severity, and time course of cancer-related neuropathic pain. To address this severe knowledge gap, we need new, high-quality, population-based studies of individual cancer pain syndromes and conditions. However, in order to gather this information, we also need substantial improvements in the specific classification of cancer-related neuropathic syndromes and better validated diagnostic tools that can help to elucidate the incidence, prevalence, severity, and potential economic impact of cancer-associated neuropathies.

UR - http://www.scopus.com/inward/record.url?scp=77956629015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956629015&partnerID=8YFLogxK

M3 - Article

C2 - 20489190

AN - SCOPUS:77956629015

VL - 15 Suppl 2

SP - 3

EP - 8

JO - Oncologist

JF - Oncologist

SN - 1083-7159

ER -